PRIMARY OUTCOMES
ASYMPTOMATIC COVID-19
In the first 6 months after randomisation, symptomatic COVID-19 occurred in 132 participants in the BCG group (adjusted estimated risk 14.7%) and in 106 participants in the placebo group (12.3%) (difference, +2.4%; 95% confidence interval [CI] −0.7% to +5.5%; p=0.13) and severe COVID-19, as defined in this trial (comprising mainly those reporting unable to work for ≥3 days), occurred in 75 participants in the BCG group (7.6%) and in 61 participants in the placebo group (6.5%) (difference, +1.1%; 95% CI −1.2% to +3.5%; p=0.34) (mITT population; 